Amgen's Nplate meets both primary endpoints
This article was originally published in Scrip
Nplate, Amgen’s fusion protein analog of thrombopoietin, achieved its primary endpoints of reducing the incidence of treatment failure and reducing the incidence of splenectomy in adults with chronic immune thrombocytopenia (ITP), according to a study published in the 10 November of the New England Journal of Medicine. The drug is already approved for chronic ITP, but this was the first study that compared a variety of ITP treatments including standard-of-care for ITP.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.